J Med Life Sci > Volume 17(2); 2020 > Article
Journal of Medicine and Life Science 2020;17(2):47-52.
DOI: https://doi.org/10.22730/jmls.2020.17.2.47    Published online August 31, 2020.
제2형 당뇨병환자에서 혈중 글루카곤 농도와 심혈관 질환 위험도의 관계
정우석1, 문재철2, 유소연1
1제주대학교 의학전문대학원 내과학교실
2제주대학교병원 내과
The relationship between glucagon levels and cardiovascular risk in patients with type 2 diabetes
Wooseok Jeong1, Jaecheol Moon2, Soyeon Yoo1
1Department of Internal Medicine, Jeju National University School of Medicine, Jeju, Republic of Korea
2Department of Internal Medicine, Jeju National University Hospital, Jeju, Republic of Korea
Correspondence:  Soyeon Yoo, Tel: 82-64-754-8149,  Email: happyweed@jejunu.ac.kr
Glucagon regulates glucose metabolism as well as fat metabolism and keton body production. The new antidiabetic drug, sodium-glucose co-transporter-2 inhibitors, that increase glucagon, reduced the risk of cardiovascular death and hospitalization for heart failure. Presence of metabolic syndrome is important risk factors for cardiovascular disease (CVD) in type 2 diabetes (T2DM) patients. We investigated the association of glucagon level with metabolic syndrome in patients with type 2 diabetes.
This is a cross-sectional study involving 317 people with type 2 diabetes. Glucagon level were measured in a fasted state and 30 min after ingestion of a standard mixed meal. Metabolic syndrome was defined by criteria of the International Diabetes Federation
Two hundred nineteen (69%) of the subjects have metabolic syndrome. The fasting glucagon level and postprandial glucagon level were no different between groups. The postprandial glucagon levels but not fasting glucagon levels increased significantly as the number of metabolic syndrome components increased. In hierarchical logistic regression analysis, the postprandial glucagon level have not been found to contribute significantly to metabolic syndrome even after adjusting for other covariates.
Taken together, fasting and postprandial glucagon levels are not associated with metabolic syndrome in patients with type 2 diabetes. However, further studies are needed to investigate the relationship between glucagon and cardiovascular risk in type 2 diabetes patients.
Key Words: glucacon, T2DM

Editorial Office
102, Jejudaehak-ro, Jeju-si, Jeju-do 63243, Republic of Korea
Tel: +82-64-754-8023    E-mail: jmls.jeju@gmail.com                

Copyright © 2024 by Jeju National University Institute for Medical Science.

Developed in M2PI

Close layer
prev next